Loading

Accession Therapeutics

June 16, 2025
Company Presentation
Oncology
Creating the ideal immunotherapy which provides potent tumour-selective delivery and tumour-selective killing ability through IV delivery. Lead program entering the clinic in 2025.
Accession Therapeutics
Company HQ City: Oxford
Company HQ State: Oxfordshire
Company HQ Country: United Kingdom
Year Founded: 2021
Lead Product in Development: TROCEPT-01 incorporates an immune checkpoint inhibitor and is expected to enter Phase 1 in Q1 2025 for treatment of solid tumours. The CTA was filed in the UK in late 2024.

CEO

Bent Jakobsen, CEO

Year Founded

2021

Development Phase of Lead Product

Phase I

When you expect your next catalyst update?

Start of Phase 1 in Q1 2025

What is your next catalyst (value inflection) update?

Q1 2025

Website

www.accessiontherapeutics.com
Primary Speaker
Steph Bewick
Steph Bewick
Chief Business Officer
Accession Therapuetics

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS